@article {3132762,
	title = {Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122},
	journal = {Gastroenterology},
	volume = {159},
	number = {3},
	year = {2020},
	note = {Chai, ChofitCox, BryanYaish, DayanaGross, DevoraRosenberg, NofarAmblard, FranckShemuelian, ZoharGefen, MaytalKorach, AmitTirosh, OrenLanton, TaliLink, HenrikeTam, JosephPermyakova, AnnaOzhan, GunesCitrin, JonathanLiao, HaixingTannous, MirnaHahn, MichalAxelrod, JonathanArretxe, EnaraAlonso, CristinaMartinez-Arranz, IbonBetes, Pablo OrtizSafadi, RifaatSalhab, AhmadAmer, JohnnyTber, ZahiraMengshetti, SeemaGiladi, HillaSchinazi, Raymond FGalun, EithanengR01 CA197081/CA/NCI NIH HHS/Research Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov{\textquoteright}tGastroenterology. 2020 Sep;159(3):999-1014.e9. doi: 10.1053/j.gastro.2020.05.056. Epub 2020 May 22.},
	month = {Sep},
	pages = {999-1014 e9},
	edition = {2020/05/26},
	abstract = {BACKGROUND \&amp; AIMS: Development of nonalcoholic steatohepatitis (NASH) is associated with reductions in hepatic microRNA122 (MIR122); the RAR related orphan receptor A (RORA) promotes expression of MIR122. Increasing expression of RORA in livers of mice increases expression of MIR122 and reduces lipotoxicity. We investigated the effects of a RORA agonist in mouse models of NASH. METHODS: We screened a chemical library to identify agonists of RORA and tested their effects on a human hepatocellular carcinoma cell line (Huh7). C57BL/6 mice were fed a chow or high-fat diet (HFD) for 4 weeks to induce fatty liver. Mice were given hydrodynamic tail vein injections of a MIR122 antagonist (antagomiR-122) or a control antagomiR once each week for 3 weeks while still on the HFD or chow diet, or intraperitoneal injections of the RORA agonist RS-2982 or vehicle, twice each week for 3 weeks. Livers, gonad white adipose, and skeletal muscle were collected and analyzed by reverse-transcription polymerase chain reaction, histology, and immunohistochemistry. A separate group of mice were fed an atherogenic diet, with or without injections of RS-2982 for 3 weeks; livers were analyzed by immunohistochemistry, and plasma was analyzed for levels of aminotransferases. We analyzed data from liver tissues from patients with NASH included in the RNA-sequencing databases GSE33814 and GSE89632. RESULTS: Injection of mice with antagomiR-122 significantly reduced levels of MIR122 in plasma, liver, and white adipose tissue; in mice on an HFD, antagomiR-122 injections increased fat droplets and total triglyceride content in liver and reduced beta-oxidation and energy expenditure, resulting in significantly more weight gain than in mice given the control microRNA. We identified RS-2982 as an agonist of RORA and found it to increase expression of MIR122 promoter activity in Huh7 cells. In mice fed an HFD or atherogenic diet, injections of RS-2982 increased hepatic levels of MIR122 precursors and reduced hepatic synthesis of triglycerides by reducing expression of biosynthesis enzymes. In these mice, RS-2982 significantly reduced hepatic lipotoxicity, reduced liver fibrosis, increased insulin resistance, and reduced body weight compared with mice injected with vehicle. Patients who underwent cardiovascular surgery had increased levels of plasma MIR122 compared to its levels before surgery; increased expression of plasma MIR122 was associated with increased levels of plasma free fatty acids and levels of RORA. CONCLUSIONS: We identified the compound RS-2982 as an agonist of RORA that increases expression of MIR122 in cell lines and livers of mice. Mice fed an HFD or atherogenic diet given injections of RS-2982 had reduced hepatic lipotoxicity, liver fibrosis, and body weight compared with mice given the vehicle. Agonists of RORA might be developed for treatment of NASH.},
	keywords = {*Lipid, *Metabolism, *nafld, *Obesity, Animals, Antagomirs/administration \& dosage, Benzamides/pharmacology/therapeutic use, Body weight, Cell Line, Tumor, Datasets as Topic, Diet, High-Fat/adverse effects, Disease Models, Animal, Fatty Acids, Nonesterified/blood/metabolism, Humans, Insulin Resistance, Lipid Metabolism/drug effects/genetics, Lipid Regulating Agents/*pharmacology/therapeutic use, Liver/drug effects/pathology, Male, Mice, MicroRNAs/antagonists \& inhibitors/blood/*genetics, Mutation, Non-alcoholic Fatty Liver Disease/*drug therapy/etiology/metabolism/pathology, Nuclear Receptor Subfamily 1, Group F, Member 1/*agonists/metabolism, Obesity/*drug therapy/etiology/metabolism/pathology, Promoter Regions, Genetic/drug effects, Up-Regulation/drug effects},
	isbn = {1528-0012 (Electronic)0016-5085 (Linking)},
	url = {https://pubmed.ncbi.nlm.nih.gov/32450149/},
	author = {Chai, C. and Cox, B. and Yaish, D. and Gross, D. and Rosenberg, N. and Amblard, F. and Shemuelian, Z. and Gefen, M. and Korach, A. and Tirosh, O. and Lanton, T. and Link, H. and Tam, J. and Permyakova, A. and Ozhan, G. and Citrin, J. and Liao, H. and Tannous, M. and Hahn, M. and Axelrod, J. and Arretxe, E. and Alonso, C. and Martinez-Arranz, I. and Betes, P. O. and Safadi, R. and Salhab, A. and Amer, J. and Tber, Z. and Mengshetti, S. and Giladi, H. and Schinazi, R.F. and Galun, E.}
}
